- Home
- VRDN vs ELME Comparison
VRDN vs ELME Comparison
Compare VRDN & ELME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRDN
- ELME
- Stock Information
- Founded
- VRDN 2006
- ELME 1960
- Country
- VRDN United States
- ELME United States
- Employees
- VRDN N/A
- ELME N/A
- Industry
- VRDN Medical Specialities
- ELME Real Estate Investment Trusts
- Sector
- VRDN Health Care
- ELME Real Estate
- Exchange
- VRDN Nasdaq
- ELME Nasdaq
- Market Cap
- VRDN 1.6B
- ELME 1.3B
- IPO Year
- VRDN N/A
- ELME N/A
- Fundamental
- Price
- VRDN $12.56
- ELME $17.19
- Analyst Decision
- VRDN Buy
- ELME Hold
- Analyst Count
- VRDN 12
- ELME 6
- Target Price
- VRDN $36.44
- ELME $17.80
- AVG Volume (30 Days)
- VRDN 718.2K
- ELME 655.1K
- Earning Date
- VRDN 05-07-2025
- ELME 04-30-2025
- Dividend Yield
- VRDN N/A
- ELME 4.19%
- EPS Growth
- VRDN N/A
- ELME N/A
- EPS
- VRDN N/A
- ELME N/A
- Revenue
- VRDN $302,000.00
- ELME $241,935,000.00
- Revenue This Year
- VRDN N/A
- ELME $4.24
- Revenue Next Year
- VRDN $17,629.40
- ELME $2.85
- P/E Ratio
- VRDN N/A
- ELME N/A
- Revenue Growth
- VRDN N/A
- ELME 6.15
- 52 Week Low
- VRDN $11.40
- ELME $13.30
- 52 Week High
- VRDN $27.20
- ELME $18.49
- Technical
- Relative Strength Index (RSI)
- VRDN 28.07
- ELME 54.43
- Support Level
- VRDN $14.03
- ELME $17.06
- Resistance Level
- VRDN $15.91
- ELME $17.62
- Average True Range (ATR)
- VRDN 0.67
- ELME 0.33
- MACD
- VRDN -0.19
- ELME -0.04
- Stochastic Oscillator
- VRDN 0.71
- ELME 44.16
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
About ELME Elme Communities
Elme Communities is a real estate investment trust engaged in owning and operating properties in the greater Washington DC metropolitan area. The company's real estate portfolio is comprised of office, retail, and multifamily properties located near transportation nodes. Washington REIT derives nearly all of its income in the form of rental revenue from tenants organized into long-term leases. The company's office assets contribute the majority of this income, while the rest is split fairly evenly between its retail and multifamily locations. Washington REIT's tenants are banking, consulting, law, and financial services firms.